Comparison of ondansetron and granisetron for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia: a prospective, randomised, and double blind study.
Kiran SavantRakshit Vijay Sinai KhandeparkerVikas BerwalPurva Vijay Sinai KhandeparkerHunny JainPublished in: Journal of the Korean Association of Oral and Maxillofacial Surgeons (2016)
Granisetron at an intravenous dose of 2 mg was found to be safe, well tolerated, and more effective by increasing the incidence of complete response compared to 4 mg intravenous ondansetron when used for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia. Benefits of granisetron include high receptor specificity and high potency, which make it a valuable alternative to ondansetron.
Keyphrases
- chemotherapy induced
- minimally invasive
- double blind
- coronary artery bypass
- clinical trial
- placebo controlled
- high dose
- surgical site infection
- open label
- study protocol
- risk factors
- randomized controlled trial
- phase ii
- phase iii
- coronary artery disease
- percutaneous coronary intervention
- low dose
- acute coronary syndrome